QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) Announces API Synthesis of Multiple Tryptamine Derivatives
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc., a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing Nov. 15, 2020, as contemplated by the terms of a contribution agreement (the “ transaction agreement”) dated Dec. 4, 2020. According to the update, the agreement is among Cybin, Cybin Corp., Cybin US Holdings Inc. (“ Acquiror ”), a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia (the “ Adelia Shareholders ”). Per the terms of the agreement, an aggregate of 51,163.1…